Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.

Journal of the National Cancer Institute - 8 Jun 2023

Wang Xiao-Shan, Bai Yi-Feng, Verma Vivek, Yu Rui-Lian, Tian Wei, Ao Rui, Deng Ying, Zhu Xue-Qiang, Liu Hao, Pan Hai-Xia, Yang Lan, Bai Han-Song, Luo Xing, Guo Yan, Zhou Ming-Xiu, Sun Yue-Mei, Zhang Zi-Can, Li Si-Min, Cheng Xue, Tan Bang-Xian, Han Liang-Fu, Liu Ying-Yi, Zhang Kai, Zeng Fan-Xin, Jia Lin, Hao Xin-Bao, Wang You-Yu, Feng Gang, Xie Ke, Lu You, Zeng Ming

Abstract excerpt

BACKGROUND: Adding radiotherapy (RT) to systemic therapy improves progression-free survival (PFS) and overall survival (OS) in oligometastatic non-small cell lung cancer (NSCLC). Whether these findings translate to epidermal growth factor receptor (EGFR)-mutated NSCLC remains unknown. The SINDAS trial (NCT02893332) evaluated first-line tyrosine kinase inhibitor (TKI) therapy for EGFR-mutated synchronous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Tyrosine Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 35094066
DOI: 10.1093/jnci/djac015
PMCID: PMC10248839

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.PMID 35094066Read ↗

A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11).Semantic proximity Read ↗

Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique.Semantic proximity Read ↗

Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial.Semantic proximity Read ↗

Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival.Semantic proximity Read ↗

Thoracic radiotherapy synergizes with first-line EGFR-TKIs in advanced EGFR-mutant NSCLC: A dual-center real-world study.Semantic proximity Read ↗

Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study.Semantic proximity Read ↗

EGFR-TKIs with or without Stereotactic Body Radiotherapy to Primary Lesion in the Advanced EGFR-Mutated Non- Small Cell Lung CancerSemantic proximity Read ↗

Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer.Semantic proximity Read ↗

First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.Semantic proximity Read ↗

Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.Semantic proximity Read ↗

Concurrent afatinib and stereotactic body radiotherapy improved survival of patient with oligometastatic EGFR-mutated non-small cell lung cancer： A case study and literature reviewSemantic proximity Read ↗

Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.